Screener
G&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-060382
| REVENUE / TOTAL REVENUE | Three Months Ended March 31, 2026 / — | Three Months Ended March 31, 2025 / — |
|---|---|---|
| OPERATING EXPENSES | ||
| Research and development | 27,376,912 | 18,915,572 |
| General and administrative | 9,395,941 | 6,067,376 |
| TOTAL OPERATING EXPENSES | 36,772,853 | 24,982,948 |
| LOSS FROM OPERATIONS | (36,772,853) | (24,982,948) |
| OTHER INCOME (EXPENSE) | ||
| Other income | 8,145 | 12,485 |
| Investment income | 2,904,506 | 729,542 |
Item 1. Financial Statements.
FAQ
- What is Capricor Therapeutics's G&A?
- Capricor Therapeutics (CAPR) reported G&A of $9.4M in Q1 2026.
- How has Capricor Therapeutics's G&A changed year-over-year?
- Capricor Therapeutics's G&A increased by 54.9% year-over-year, from $6.07M to $9.4M.
- What is the long-term trend for Capricor Therapeutics's G&A?
- Over 4 years (2021 to 2025), Capricor Therapeutics's G&A has grown at a 32.8% compound annual growth rate (CAGR), from $7.61M to $23.69M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Capricor Therapeutics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude